On November 5, Premier Biotech announced that it acquired National Test Systems (NTS) for an undisclosed price.
NTS is a leading provider of rapid point-of-care diagnostic drug screening supplies and services throughout the United States. NTS serves more than 1,500 facilities and is based in Boca Raton, Florida.
Premier Biotech delivers rapid and innovative diagnostic solutions that promote health, safety and compliance. The company is a leading provider of proprietary oral fluid (OralTox® and OT-Scan®) and other products, services and technology solutions designed to simplify and provide a seamless end-to-end experience for customers. Premier Biotech’s integrated offering is utilized in the workplace, government and healthcare settings. The company was acquired by private equity firm Align Capital Partners in December 2022.
“The acquisition marks a pivotal step in our growth journey and bolsters our leadership position across the drug and alcohol testing industry,” said Premier CEO Matt Michalik. “NTS adds meaningful client depth to our Government and Behavioral Health businesses, complementary point-of-care testing solutions with cross sell potential and a fantastic team to our growing organization. We are thrilled for this partnership.”
According to data captured in the LevinPro HC database, this transaction marks the 109th Laboratories, MRI and Dialysis transaction of the year, and the 61st in the diagnostic subsector. Throughout all of 2024, there were 121 Laboratories, MRI and Dialysis transactions, 64 of them in the diagnostic subsector.
